Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer.

Yuji Kobayashi(Aichi Cancer Center), Kenji Yamao(Aichi Cancer Center), Akira Sawaki(Aichi Cancer Center), Kazuo Hara(Aichi Cancer Center), Nobumasa Mizuno(Aichi Cancer Center), Keitaro Matsuo(Aichi Cancer Center), Hidewaki Nakagawa(RIKEN Center for Integrative Medical Sciences), Susumu Hijioka(Aichi Cancer Center), Yusuke Nakamura(Rissho University), Shinya Kondo(Aichi Cancer Center), H. Kawai(Aichi Cancer Center), Yasumasa Niwa(Aichi Cancer Center), Masahiro Tajika(Aichi Cancer Center)
PubMed
April 21, 2011
Cited by 16

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy
|Nature|1998|804
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749